Skip to content

Effect of the Pippalyadi loham (oral) in the management of Tamaka swasa (Bronchial Asthma)

A clinical study to evaluate the efficacy of Pippalyadi loham in the management of Tamaka Swasa wsr to Bronchial Asthma

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/112476
Enrollment
30
Registered
2026-06-10
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J984- Other disorders of lung Health Condition 2: J988- Other specified respiratory disorders

Interventions

None listed

Sponsors

Dr BRKR Govt Ayurvedic Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged between 20 to 60 years irrespective of gender Patients presenting with the classical Symptoms of Tamaka Swasa such as Dyspnoea, Profuse Sweating over the forehead, Wheezing Cough, Sputum production, Relief after expectoration of sputum, Relief in sitting posture Mild persistent cases of Asthma as per WHO GINA Guidelines of duration more than 6 months Night symptoms greater than twice per month but less than twice a week Forced Expiratory Volume in one second FEV1 greater than 80% of the predicted value SpO2 greater than 92 percentage Currently Non-smokers

Exclusion criteria

Exclusion criteria: Patients aged below 20 years and above 60 years. Moderate and Severe persistent Asthma. Asthma due to other systemic origin. Cardiac Asthma, Status Asthmaticus, CVDs, Uncontrolled Diabetes HbA1c greater than 9 percentage, Autoimmune diseases. SpO2 less than 92 percentage HIV Positive cases. Pregnant women and lactating mothers. Dyspnoea due to other diseases like COPD Emphysema, Bronchiectasis, Pulmonary Tuberculosis, Interstitial Lung Disease occupational lung diseases, Malignancies.

Design outcomes

Primary

MeasureTime frame
To reduce the frequency of episodes of Shortness of Breath Timepoint: 60 days

Secondary

MeasureTime frame
To reduce the symptoms of Bronchial AsthmaTimepoint: 60 days

Countries

India

Contacts

Public ContactDr K Aruna Gayithri

Dr BRKR Govt Ayurvedic Medical College and Hospital

ketharajugayathri@gmail.com9490285547

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026